Jerusalem/Needham (PRWEB) January 9, 2011
Oridion (SIX Swiss Exchange: ORIDN), creator of the Smart Capnography™ family of algorithm-based solutions, today announced that the Oridion Capnostream® 20 bedside monitor is now available for sale with the Masimo Patient SafetyNet™ remote monitoring and clinician notification system. The Capnostream 20 is the latest portable bedside monitor providing capnography, supporting monitoring of adequacy of ventilation and early indication of airway compromise.
This advancement follows a 2009 agreement between Oridion and Masimo (NASDAQ: MASI), the inventor of Pulse CO-Oximetry™ and Measure-Through Motion and Low Perfusion pulse oximetry, that established connectivity between the Capnostream 20 monitors and the Masimo Patient SafetyNet.
The Oridion Capnostream® 20 bedside patient monitor with Microstream® technology, together with the Masimo® Patient SafetyNet system, provide two measurement technologies (capnography and pulse oximetry) widely recognized to provide patient safety on the general care floor.
It is the first remote monitoring and clinician notification system to feature the Oridion Smart Capnography™ innovation, the Integrated Pulmonary Index™ (IPI), enabling real-time tracking and trending of Oridion etCO2 and respiration rate in combination with Masimo SET® SpO2 and pulse rate, for a comprehensive assessment of the patient's oxygenation and ventilatory status.
This powerful solution combines industry-proven performance and measurements for monitoring oxygenation and ventilation in an easy-to-use device for both hospital and outpatient environments. It also offers the added safety associated with remote monitoring and automated clinician notification (Masimo SafetyNet) of adverse changes in a patient's status. This system can either be integrated into an existing IT infrastructure or operate as a stand-alone system.
The Capnostream 20 is the first device that utilizes IPI, the newest Oridion Smart Capnography™ innovation. Smart Capnography - Integrated Pulmonary Index, SARA™ (Smart Alarm Respiratory Analysis) and Smart Breath Detection Algorithm™ - are a family of algorithm-based solutions developed by Oridion to improve patient safety and clinical workflow. IPI integrates capnography and pulse oximetry values into a single, easy-to-understand index, simplifying assessment of patient ventilation status.
The Masimo Patient SafetyNet remote monitoring and clinician notification system combines Masimo SET® pulse oximetry with respiration rate monitoring and wireless clinician notification via pager. Masimo SET provides accurate and reliable pulse oximetry, clinically proven in more than 100 independent and objective studies to provide trustworthy SpO2 and pulse rate measurements.
Medical professionals have been impressed with the Capnostream 20 with IPI, reacting very favorably to its ease of use, its accuracy, and its importance for nurses and medical staff who strive to continuously improve patient safety and care.
"I feel that my patients are safer with the Capnostream 20 monitor because it gives a better overall picture and assessment of the patient's condition," said Kellie McKinney, RRT, manager of a respiratory center responsible for weaning ICU patients off of ventilators. "The quicker I can look at something with the least number of parameters to absorb the more efficient and productive I can be for my patient. IPI makes that easy. We found that IPI was the key number we needed to assess the patients' overall condition and give us the best picture of their status. A patient can be doing less well in one area but doesn't require intervention, and IPI recognizes that."
McKinney and her team were impressed with the Capnostream 20's ease of use and trending capabilities.
"With the 72-hour trending, if someone has had an event, it gives me a quicker picture to make decisions on care, whether they need to be seen by a specialist," she said. "That's very important."
Smart Capnography can be found only in Microstream capnography-equipped patient monitors, including the Oridion Capnostream 20. The Capnostream 20 enables patient monitoring in clinical environments where procedural sedation and pain management is administered and patients are at risk for opioid induced respiratory depression and arrest, particularly for sedation procedures and patient controlled analgesia (PCA).
"With the introduction of IPI to the Smart Capnography suite, the Oridion Capnostream 20 provides a reliable and accurate assessment tool for a patient's ventilatory status in a simple value that enables clinicians to make patient care decisions. The direct result is improved patient care, as well as enhanced communication among clinicians," said Gerry Feldman, President of Oridion Capnography Inc. "Masimo Patient SafetyNet offers the added safety associated with remote monitoring and automated clinician notification of adverse changes in a patient's status. Bringing together these two technologies results in optimal monitoring options and advanced surveillance solutions for healthcare facilities seeking to improve patient safety and clinical outcomes."
IPI is also expected to be included in the patient monitoring systems of several of Oridion's other OEM partners in the coming 1-2 years.
For further Oridion information please contact
Alan Adler, Chairman and Chief Executive Officer
Walter Tabachnik, Chief Financial Officer
Elena Gerberg, Investor Relations
e-mail investor (at) oridion (dot) com
phone +972 2 589 9159
address Oridion Systems Ltd., P.O. Box 45025, 91450 Jerusalem, Israel
Oridion Systems Ltd. (http://www.oridion.com) is a global medical device company specializing in patient safety monitoring. The Company operates through wholly owned subsidiaries in Israel and the United States.
Oridion develops proprietary medical devices and patient interfaces, based on its patented Microstream® technologies, for the enhancement of patient safety through the monitoring of the carbon dioxide (CO2) in a patient's breath. These products provide effective, proven airway management and are used in various clinical environments, including procedural sedation, pain management, critical care units, post-anesthesia care units, emergency medical services, transport, alternate care and other settings where patients' ventilation may be compromised and at risk.
Certain statements made herein that are not historical are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995.
The words "estimate" "project" "intend" "expect" "believe" and similar expressions are intended to identify forward-looking statements. These forward-looking statements involve known and unknown risks and uncertainties. Many factors could cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements that may be expressed or implied by such forward-looking statements, including, among others, our ability to maintain profits, the market demands for our Capnography products, our ability to focus our team on the Capnography business, changes in general economic and business conditions, inability to maintain market acceptance to the Company's products, inability to timely develop and introduce new technologies, products and applications, rapid changes in the market for the Company's products, loss of market share and pressure on prices resulting from competition, introduction of competing products by other companies, inability to manage growth and expansion, loss of key OEM partners, inability to attract and retain qualified personnel, inability to protect the Company's proprietary technology. The Company does not assure any obligation to update the forward looking information contained in this press release.